Dyadic International Inc. (NASDAQ:DYAI) Short Interest Down 52.2% in July

Posted by George Bondi on Jul 28th, 2026

Dyadic International Inc. (NASDAQ:DYAI – Get Free Report) saw a significant decrease in short interest in July. As of July 15th, there was short interest totaling 83,534 shares, a decrease of 52.2% from the June 30th total of 174,705 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily volume of 326,346 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of DYAI. Bank of America Corp DE grew its stake in shares of Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 26,965 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 36,266 shares during the last quarter. Marathon Capital Management boosted its holdings in Dyadic International by 142.9% during the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 50,000 shares during the period. Finally, Landscape Capital Management L.L.C. purchased a new position in Dyadic International during the 3rd quarter valued at $190,000. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Dyadic International Trading Down 1.8%

Shares of DYAI traded down $0.02 during midday trading on Tuesday, hitting $1.11. The stock had a trading volume of 280,761 shares, compared to its average volume of 181,173. Dyadic International has a 1 year low of $0.65 and a 1 year high of $1.60. The firm has a market cap of $40.45 million, a PE ratio of -4.87 and a beta of 1.15. The company has a debt-to-equity ratio of 4.08, a current ratio of 2.42 and a quick ratio of 2.42. The stock’s 50 day moving average is $0.90 and its 200 day moving average is $0.85.

Dyadic International (NASDAQ:DYAI – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The firm had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. As a group, analysts forecast that Dyadic International will post 0.13 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Dyadic International presently has an average rating of “Hold” and a consensus price target of $3.00.

View Our Latest Research Report on DYAI

About Dyadic International

(Get Free Report)

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.